Edition:
United States

Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

1.38USD
24 May 2017
Change (% chg)

$0.02 (+1.47%)
Prev Close
$1.36
Open
$1.37
Day's High
$1.40
Day's Low
$1.36
Volume
1,434,111
Avg. Vol
2,230,342
52-wk High
$2.16
52-wk Low
$1.13

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals reports Q1 loss per share $0.09
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals provides corporate update and reports first quarter 2017 financial results.Q1 loss per share $0.09.Q1 revenue $6.6 million versus I/B/E/S view $8.1 million.Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc says Ralinepag phase 2 study results expected in July.  Full Article

Arena Pharmaceuticals prices 60 mln shares of common stock at price of $1.15/share
Monday, 17 Apr 2017 10:15pm EDT 

April 17 (Reuters) - Arena Pharmaceuticals Inc :Arena Pharmaceuticals announces pricing of public offering of common stock.Priced an underwritten public offering of 60 million shares of its common stock, at a price of $1.15 per share.  Full Article

Arena Pharmaceuticals announces proposed public offering of common stock
Monday, 17 Apr 2017 04:01pm EDT 

April 17 (Reuters) - Arena Pharmaceuticals Inc -:Arena Pharmaceuticals announces proposed public offering of common stock.  Full Article

Arena Pharma qtrly net income $38.3 mln or $0.16 per share
Tuesday, 14 Mar 2017 04:01pm EDT 

Arena Pharmaceuticals Inc : Arena pharmaceuticals provides corporate update and reports fourth quarter and full-year 2016 financial results . Arena pharmaceuticals inc - qtrly revenues totaled $85.4 million . Arena pharmaceuticals inc - qtrly net income was $38.3 million or $0.16 per share .Arena pharma- expects fy17 net cash used in operating,investing activities to be $80 to $100 million, assuming no additional partnerships.  Full Article

Arena Pharmaceuticals completes enrollment in phase 2 clinical trial for PAH
Wednesday, 7 Dec 2016 08:30am EST 

Arena Pharmaceuticals Inc : Arena Pharmaceuticals - look forward to seeing results from Phase 2 trial mid-year . Arena Pharmaceuticals Inc - study enrolled approximately 60 patients at sites globally .Arena Pharmaceuticals completes enrollment in ralinepag phase 2 clinical trial for pulmonary arterial hypertension (PAH).  Full Article

Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'
Thursday, 25 Aug 2016 06:20am EDT 

Arena Pharmaceuticals Inc : Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq . Notification is currently under investigation . Co and Eisai have 45 days from receipt of notification to file a patent infringement suit against ANDA filer .Patent infringement suit would result in stay of FDA approval of ANDA under statutory guidelines.  Full Article

Arena Pharmaceuticals reports Q2 loss per share $0.11
Monday, 8 Aug 2016 04:01pm EDT 

Arena Pharmaceuticals Inc : Arena Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 revenue $9.5 million versus I/B/E/S view $10.4 million . Q2 loss per share $0.11 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Arena Pharma, EISAI announce FDA approval of BELVIQ XR extended-release tablets
Tuesday, 19 Jul 2016 08:26am EDT 

Arena Pharmaceuticals Inc : BELVIQ XR is expected to be available in fall of 2016. . Arena pharmaceuticals inc says in connection with approval, arena will receive a $10 million milestone payment. . EISAI Inc and Arena Pharmaceuticals announce FDA approval of Belviq XR (lorcaserin HCL) extended-release tablets .In connection with approval, arena will receive a $10 million milestone payment.  Full Article

Eisai, Arena announce regulatory approval of VENESPRI in Mexico
Thursday, 14 Jul 2016 08:05am EDT 

Arena Pharmaceuticals Inc : Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI® (lorcaserin HCl) in Mexico . In connection with the approval, Arena will receive a $1 million milestone payment . In connection with the approval, Arena will receive a $1 million milestone payment .VENESPRI® is expected to become available later this year.  Full Article

Arena Pharmaceuticals to emphasize on its proprietary clinical stage pipeline
Thursday, 30 Jun 2016 04:05pm EDT 

Arena Pharmaceuticals: Arena Pharmaceuticals Inc says strategic shifting of priorities to emphasize its proprietary clinical stage pipeline . Arena Pharmaceuticals Inc says implementation of additional cost reductions to streamline organization to support its development programs . Arena pharmaceuticals inc says will reduce its us workforce by approximately 100 employees, or 73%, primarily in areas of research, manufacturing and G&A . Estimates cost reductions to result in reduced cash expenditures for personnel by about $17 million . Plans to implement additional cost control measures to further reduce expenditures, including reductions at Swiss manufacturing facility .As a result of us workforce reduction, estimates it will incur restructuring charges, primarily in q2 of 2016, of about $6.1 million.  Full Article

More From Around the Web

BRIEF-Arena Pharmaceuticals reports Q1 loss per share $0.09

* Arena Pharmaceuticals provides corporate update and reports first quarter 2017 financial results